101 related articles for article (PubMed ID: 9891537)
1. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas.
Ramondetta LM; Palazzo JP; Dunton CJ; Kovatich AJ; Carlson JA
Anticancer Res; 1998; 18(6B):4661-5. PubMed ID: 9891537
[TBL] [Abstract][Full Text] [Related]
2. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
Choi HR; Tucker SA; Huang Z; Gillenwater AM; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2003 Feb; 22(2):409-14. PubMed ID: 12527941
[TBL] [Abstract][Full Text] [Related]
3. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.
Nikaido T; Li SF; Shiozawa T; Fujii S
Cancer; 1996 Sep; 78(6):1248-53. PubMed ID: 8826947
[TBL] [Abstract][Full Text] [Related]
4. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma.
Cheng JD; Werness BA; Babb JS; Meropol NJ
Clin Cancer Res; 1999 May; 5(5):1057-62. PubMed ID: 10353738
[TBL] [Abstract][Full Text] [Related]
6. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
8. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
[TBL] [Abstract][Full Text] [Related]
13. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
[TBL] [Abstract][Full Text] [Related]
14. Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis.
Arai N; Mitomi H; Ohtani Y; Igarashi M; Kakita A; Okayasu I
Mod Pathol; 1999 Jun; 12(6):604-11. PubMed ID: 10392637
[TBL] [Abstract][Full Text] [Related]
15. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S
Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.
Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH
Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N
Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
20. Loss of p21 expression is associated with p53 mutations and increased cell proliferation and p27 expression is associated with apoptosis in maxillary sinus squamous cell carcinoma.
Bandoh N; Hayashi T; Takahara M; Kishibe K; Ogino T; Katayama A; Imada M; Nonaka S; Harabuchi Y
Acta Otolaryngol; 2005 Jul; 125(7):779-85. PubMed ID: 16012042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
